← FDA Drug Approvals (Drugs@FDA)
CABAZITAXEL
ANDA · Abbreviated New Drug Application (Generic) · Sponsor: BPI LABS LLC · Approved 2023-03-22
Drug application
- FDA Application #
ANDA207735- Application type
- Abbreviated New Drug Application (Generic)
- Brand name
- CABAZITAXEL
- Generic name
- Cabazitaxel
- Active ingredients
- CABAZITAXEL
- Dosage form
- UNKNOWN
- Route
- UNKNOWN
- Marketing status
- None (Tentative Approval)
- Sponsor
- BPI LABS LLC
- First approval
- 2023-03-22
Source
- Authoritative
- Drugs@FDA application overview
- Machine
- JSON-LD · Markdown